Analysis of ultralow expression of human epidermal growth factor receptor 2 in breast carcinoma
Objective To investigate the ultralow expression of human epidermal growth factor receptor 2(HER2)in patients with HER2 0 breast cancer.Methods The 107 breast cancer specimens collected in the from January 2021 to December 2022.The expression of HER2 was detected by using immunohistochemistry(IHC).The HER2 expression was assessed according to the HER2 ultralow expression standard.Results Among the 107 cases that were previously detected as HER2 IHC 0,7 were assessed as 1+,including 6 radical resection samples and 1 biopsy sample,and IHC 0 100 cases.Among the 100 HER2 IHC 0 samples,56 had HER2 ultralow expression and 44 had HER2 null.The HER2 ultralow ex-pression rate of radical resection samples was55.17%(48/87),the biopsy samples of 61.54%(8/13),and the differ-ence was not statistically significant(χ2=0.186,P=0.667).The HER2 ultralow expression rate of lymph node metastasis samples was48.00%(12/25)and the rate of no lymph node metastasis samples was58.67%(44/75),and the differ-ence was not statistically significant(χ2=0.866,P=0.352).Conclusion The HER2 ultralow expression is more com-mon in HER2 0 breast cancer,and there is no correlation with surgical methods and lymph node metastasis.
breast carcinomahuman epidermal growth factor receptor 2ultralow expression
万方数据
维普
